Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: A prospective randomized clinical trial

International Ophthalmology

Volumn 33, Issue 1, 2013, Pages 39-46

  Baharivand, Nader ^a   Mahdavifard, Ali ^a   Fouladi, Rohollah Fadaei ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Clindamycin; Dexamethasone; Folinic acid; Intravitreal injection; Prednisone; Pyrimethamine; Sulfadiazine; Toxoplasmic retinochoroiditis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CLINDAMYCIN PLUS DEXAMETHASONE; FOLINIC ACID; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PREDNISONE; PYRIMETHAMINE; SULFADIAZINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BEST CORRECTED VISUAL ACUITY; CHORIORETINITIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; INJECTION SITE REACTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SINGLE BLIND PROCEDURE; TOXOPLASMIC RETINOCHOROIDITIS; TREATMENT OUTCOME; VISUAL ACUITY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; CHORIORETINITIS; CLINDAMYCIN; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MALE; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TOXOPLASMA; TOXOPLASMOSIS, OCULAR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872314364     PISSN: 01655701     EISSN: 15732630     Source Type: Journal    
DOI: 10.1007/s10792-012-9634-1     Document Type: Article

References (41)

1. Henderly DE, Genstler AJ, Smith RE et al (1987) Changing patterns of uveitis. Am J Ophthalmol 103:131-136
2. Tabbara KF (1995) Ocular toxoplasmosis: toxoplasmic retinochoroiditis. Int Ophthalmol Clin 35:15-29
3. American Academy of Ophthalmology (2011) Focal points: clinical modules for ophthalmologists. American Academy of Ophthalmology, San Francisco
4. Nussenblatt RB, Whitcup SM, Palestine AG (1995) Uveitis: fundamentals in clinical practice. Mosby, St. Louis
5. Engstrom RE Jr, Holland GN, Nussenblatt RB et al (1991) Current practices in the management of ocular toxoplasmosis. Am J Ophthalmol 111:601-610
6. Wertheim MS, Smith JR, Cunningham ET et al (2004) Toxoplasmosis can test diagnostic skills. Rev Ophthalmol 11:140
7. Rothova A, Meenken C, Buitenhuis HJ et al (1993) Therapy for ocular toxoplasmosis. Am J Ophthalmol 115:517-523
8. Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS et al (2002) A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am J Ophthalmol 134:34-40
9. Ferguson JG Jr (1981) Clindamycin therapy for toxoplasmosis. Ann Ophthalmol 13:95-100
10. Martinez CE, Zhang D, Conway MD et al (1998-1999) Successful management of ocular toxoplasmosis during pregnancy using combined intraocular clindamycin and dexamethasone with systemic sulfadiazine. Int Ophthalmol 22:85-88
11. Soheilian M, Ramezani A, Azimzadeh A et al (2011) Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology 118:134-141
12. Dodds EM, Holland GN, Stanford MR et al (2008) Intraocular inflammation associated with ocular toxoplasmosis: relationships at initial examination. Am J Ophthalmol 146:856-865
13. Kanski JJ (2007) Clinical ophthalmology: a systematic approach. Butterworth-Heinemann, Oxford
14. Kimura SJ, Thygeson P, Hogan M (1959) Signs and symptoms of uveitis. II. Classification of the posterior manifestations of uveitis. Am J Ophthalmol 47:171-176
15. Lam S, Tessler HH (1993) Quadruple therapy for ocular toxoplasmosis. Can J Ophthalmol 28:58-61
16. Guldsten H (1983) Clindamycin and sulphonamides in the treatment of ocular toxoplasmosis. Acta Ophthalmol (Cph) 61:51-57
17. Tabbara KF, Nozik RA, O'Connor GR (1974) Clindamycin effects on experimental ocular toxoplasmosis in the rabbit. Arch Ophthalmol 92:244-247
18. Zimmerman TJ, Kooner KS, Sharir M, Fechtner RD (1997) Text book of ocular pharmacology. Lippincott Williams & Wilkins, Philadelphia
19. Norrby R (1978) A review of the penetration of antibiotics into CSF and its clinical significance. Scand J Infect Dis Suppl 14:296-309
20. Keusch GT, Present DH (1976) Summary of a workshop on clindamycin colitis. J Infect Dis 133:578-587
21. Reeves DS, Wilkinson PJ (1979) The pharmacokinetics of trimethoprim and trimethoprim/sulphonamide combinations, including penetration into body tissues. Infection 7:S330-S341
22. Weiss LM, Harris C, Berger M et al (1988) Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS. J Infect Dis 157:580-583
23. Kaufman HE (1961) The penetration of daraprim (pyrimethamine) into the monkey eye. Am J Ophthalmol 52:402-404
24. Katlama C, De Wit S, O'Doherty E et al (1996) Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 22:268-275
25. Luft BJ, Hafner R, Korzun AH et al (1993) Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 329:995-1000
26. Wine NA, Gornall AG, Basu PK (1964) The ocular uptake of subconjunctivally injected C14 hydrocortisone. 1. Time and major route of penetration in a normal eye. Am J Ophthalmol 58:362-366
27. Benzina Z, Chaabouni S, Hentati N et al (2005) Recurrent toxoplasmic retinochoroiditis after clindamycin treatment. J Fr Ophtalmol 28:958-964
28. Tabbara KF, O'Connor GR (1975) Ocular tissue absorption of clindamycin phosphate. Arch Ophthalmol 93:1180-1185
29. Fichera ME, Bhopale MK, Roos DS (1995) In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob Agents Chemother 39:1530-1537
30. Peyman GA, Schulman JA (1994) Intravitreal surgery: principles and practice. Appleton & Lange, Norwalk
31. Peyman GA, Meffert SA, Chou F, Conway MD (2001) Vitreoretinal surgical techniques. Taylor & Francis, London
32. Lee PJ, Seal DV, Peyman GA (2004) Endophthalmitis: diagnosis and management. Informa Healthcare, London
33. Nussenblatt RB, Gery I, Ballintine EJ et al (1980) Cellular immune responsiveness of uveitis patients to retinal S-antigen. Am J Ophthalmol 89:173-179
34. Abrahams IW, Gregerson DS (1982) Longitudinal study of serum antibody responses to retinal antigens in acute ocular toxoplasmosis. Am J Ophthalmol 93:224-231
35. Whittle RM, Wallace GR, Whiston RA et al (1998) Human antiretinal antibodies in toxoplasma retinochoroiditis. Br J Ophthalmol 82:1017-1021
36. Kishore K, Conway MD, Peyman GA (2001) Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis. Ophthalmic Surg Lasers 32:183-192
37. Pague JT, Peyman GA (1974) Intravitreal clindamycin phosphate in the treatment of vitreous infection. Ophthalmic Surg 5:34-39
38. Sobrin L, Kump LI, Foster CS (2007) Intravitreal clindamycin for toxoplasmic retinochoroiditis. Retina 27:952-957
39. Soheilian M, Sadoughi MM, Ghajarnia M et al (2005) Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology 112:1876-1882
40. Lasave AF, Díaz-Llopis M, Muccioli C et al (2010) Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months. Ophthalmology 117:1831-1838
41. Soheilian M, Rafati N, Peyman GA (2001) Prophylaxis of acute posttraumatic bacterial endophthalmitis with or without combined intraocular antibiotics: a prospective, double-masked randomized pilot study. Int Ophthalmol 24:323-330